River Edge, NJ, United States of America

Jianxin Gu

This inventor holds 34 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Glycoconjugation Chemistry. Top assignees: Pfizer Corporation, Wyeth, Wyeth Holdings Corporation. Active years: 2006-2026.

USPTO Granted Patents = 34 (Patent Applications = 10)

% Patents Active = 79.4

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 8 (Patent Applications = 13)

Average Co-Inventor Count = 4.2

ph-index = 9

Forward Citations = 218(Granted Patents)

Location History:

New Milford, NJ (US) (2006)
River Edge, NJ (US) (2007 - 2020)
Paramus, NJ (US) (2016 - 2024)

Company Filing History:

Wyeth Holdings Corporation

patents

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Glycoconjugation

Immunogenic Compositions

Capsular Polysaccharides

Synthesis Processes

Calicheamicin Derivatives

Rapamycin Conjugates

Glycoprotein Conjugates

Polysaccharide Antigens

Enzymatic Synthesis

Immunosuppressants

Dicarboxylic Acid

17-Hydroxywortmannin

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12636374 - IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF (2026-05-26),

2. 12616744 - Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof (2026-05-05),

3. 12447203 - Glycoconjugation processes and compositions (2025-10-21),

4. 12343389 - capsular polysaccharides and conjugates thereof (2025-07-01),

5. 12128095 - compositions and methods thereof (2024-10-29),

6. 11872274 - Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof (2024-01-16),

7. 11723965 - Glycoconjugation processes and compositions (2023-08-15),

8. 11707529 - Immunogenic glycoprotein conjugates (2023-07-25),

9. 11426456 - [object Object] (2022-08-30),

10. 11260119 - compositions and methods thereof (2022-03-01),

11. 11160855 - Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof (2021-11-02),

12. 11110160 - Glycoconjugation processes and compositions (2021-09-07),

13. 11090375 - Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof (2021-08-17),

14. 10946086 - Group Bpolysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof (2021-03-16),

15. 10918708 - capsular polysaccharides and conjugates thereof (2021-02-16),

Title: Innovations and Contributions of Jianxin Gu in Immunogenic Compositions

Introduction

Jianxin Gu, based in River Edge, NJ, is a distinguished inventor with a prolific portfolio of 30 patents. His innovative contributions primarily focus on the field of immunogenic compositions, showcasing advanced methodologies and unique formulations that have significant implications for healthcare and vaccination.

Latest Patents

Among his latest inventions, Jianxin Gu has developed innovative immunogenic compositions that utilize modified O-polysaccharide molecules derived from lipopolysaccharides. These inventions detail methods for creating multivalent vaccines by combining various monovalent immunogenic compositions targeting different serotypes. One embodiment emphasizes the production of these polysaccharide molecules through a recombinant bacterium containing a wzz gene. Additionally, Gu has developed immunogenic compositions featuring conjugated capsular saccharide antigens, designed for vaccination against pneumococcal infections, particularly in vulnerable populations such as infants and the elderly.

Career Highlights

Jianxin Gu's career boasts tenure at reputable organizations, including Pfizer Corporation and Wyeth. His experience in these companies has not only advanced his own expertise but also contributed to the development of critical healthcare solutions that aim to combat infectious diseases through innovative vaccine formulations.

Collaborations

Throughout his career, Jianxin Gu has collaborated with notable professionals in the field, including Jin-Hwan Kim and Avvari Krishna Prasad. These collaborations have fostered an environment of innovation and have significantly enhanced the scope and impact of their collective work.

Conclusion

In summary, Jianxin Gu stands out as a leading inventor in the realm of immunogenic compositions, with a robust patent portfolio that continues to push the boundaries of vaccine technology. His work not only exemplifies cutting-edge scientific innovation but also holds the potential to improve public health through advanced immunization strategies.